1. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444-52.
2. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 2008;19:2282-7.
3. Grande MT, Perez-Barriocanal F, Lopez-Novoa JM. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. J Inflamm (Lond). 2010;7:19.
4. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212-22.
5. Garcia-Sanchez O, Lopez-Hernandez FJ, Lopez-Novoa JM. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int. 2010;77:950-5.
6. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-92.
7. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol. 2003;284:F243-52.
8. Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system. Kidney Int. 1998;53:631-8.
9. Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325-38.
10. Chen J, Hu Y, Mou X, Wang H, Xie Z. Amygdalin alleviates renal injury by suppressing inflammation, oxidative stress and fibrosis in streptozotocin-induced diabetic rats. Life Sci. 2021;265:118835.
11. Huang F, Zhao Y, Wang Q, Hillebrands JL, van den Born J, Ji L, et al. Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFbeta1 Signaling. Front Endocrinol (Lausanne). 2019;10:441.
12. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 2010;21:1878-90.
13. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257-63.
14. Devaraj S, Jialal I, Yun JM, Bremer A. Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism. 2011;60:256-9.
15. Kaur H, Chien A, Jialal I. Hyperglycemia induces Toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol. 2012;303:F1145-50.
16. Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, et al. TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol. 2010;21:1299-308.
17. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327-40.
18. Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000;275:11058-63.
19. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000;129:77-97.
20. Gaikwad A, Long DJ, 2nd, Stringer JL, Jaiswal AK. In vivo role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the regulation of intracellular redox state and accumulation of abdominal adipose tissue. J Biol Chem. 2001;276:22559-64.
21. Oh GS, Lee SB, Karna A, Kim HJ, Shen A, Pandit A, et al. Increased Cellular NAD(+) Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice. Tuberc Respir Dis (Seoul). 2016;79:257-66.
22. Shen A, Kim HJ, Oh GS, Lee SB, Lee SH, Pandit A, et al. NAD(+) augmentation ameliorates acute pancreatitis through regulation of inflammasome signalling. Sci Rep. 2017;7:3006.
23. Zhou X, Sun X, Gong X, Yang Y, Chen C, Shan G, et al. Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-small ka, CyrillicB in vivo and in vitro. Int Immunopharmacol. 2017;42:18-24.
24. Sharma D, Bhattacharya P, Kalia K, Tiwari V. Diabetic nephropathy: New insights into established therapeutic paradigms and novel molecular targets. Diabetes Res Clin Pract. 2017;128:91-108.
25. Yang F, Li B, Dong X, Cui W, Luo P. The beneficial effects of zinc on diabetes-induced kidney damage in murine rodent model of type 1 diabetes mellitus. J Trace Elem Med Biol. 2017;42:1-10.
26. Hong GL, Kim KH, Lee CH, Kim TW, Jung JY. NQO1 Deficiency Aggravates Renal Injury by Dysregulating Vps34/ATG14L Complex during Autophagy Initiation in Diabetic Nephropathy. Antioxidants (Basel). 2021;10.
27. Wu X, Pan C, Chen R, Zhang S, Zhai Y, Guo H. BML-111 attenuates high glucose-induced inflammation, oxidative stress and reduces extracellular matrix accumulation via targeting Nrf2 in rat glomerular mesangial cells. Int Immunopharmacol. 2020;79:106108.
28. Katikireddy KR, White TL, Miyajima T, Vasanth S, Raoof D, Chen Y, et al. NQO1 downregulation potentiates menadione-induced endothelial-mesenchymal transition during rosette formation in Fuchs endothelial corneal dystrophy. Free Radic Biol Med. 2018;116:19-30.
29. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, et al. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol. 2006;17:3325-35.
30. Simonson MS. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int. 2007;71:846-54.
31. Meng XM, Tang PM, Li J, Lan HY. TGF-beta/Smad signaling in renal fibrosis. Front Physiol. 2015;6:82.
32. Jia Q, Yang R, Liu XF, Ma SF, Wang L. Genistein attenuates renal fibrosis in streptozotocininduced diabetic rats. Mol Med Rep. 2019;19:423-31.
33. Gorin Y, Block K. Nox as a target for diabetic complications. Clin Sci (Lond). 2013;125:361-82.
34. Zhang S, Xu H, Yu X, Wu Y, Sui D. Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med. 2017;14:383-90.
35. Ho C, Lee PH, Hsu YC, Wang FS, Huang YT, Lin CL. Sustained Wnt/beta-catenin signaling rescues high glucose induction of transforming growth factor-beta1-mediated renal fibrosis. Am J Med Sci. 2012;344:374-82.
36. Huang K, Zhao X. USP9X prevents AGEs-induced upregulation of FN and TGF-beta1 through activating Nrf2-ARE pathway in rat glomerular mesangial cells. Exp Cell Res. 2020;393:112100.
37. Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep. 2006;6:463-8.
38. Park JE, Park JS, Leem YH, Kim DY, Kim HS. NQO1 mediates the anti-inflammatory effects of nootkatone in lipopolysaccharide-induced neuroinflammation by modulating the AMPK signaling pathway. Free Radic Biol Med. 2021;164:354-68.
39. Li Q, Karim AF, Ding X, Das B, Dobrowolski C, Gibson RM, et al. Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis. Sci Rep. 2016;6:27566.
40. Holdsworth SR, Summers SA. Role of mast cells in progressive renal diseases. J Am Soc Nephrol. 2008;19:2254-61.
41. Ma J, Chadban SJ, Zhao CY, Chen X, Kwan T, Panchapakesan U, et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One. 2014;9:e97985.
42. Huang Q, Bai F, Nie J, Lu S, Lu C, Zhu X, et al. Didymin ameliorates hepatic injury through inhibition of MAPK and NF-kappaB pathways by up-regulating RKIP expression. Int Immunopharmacol. 2017;42:130-38.
43. Kimura A, Kitajima M, Nishida K, Serada S, Fujimoto M, Naka T, et al. NQO1 inhibits the TLR-dependent production of selective cytokines by promoting IkappaB-zeta degradation. J Exp Med. 2018;215:2197-209.
44. Lee SI, Park KH, Kim SJ, Kang YG, Lee YM, Kim EC. Mechanical stress-activated immune response genes via Sirtuin 1 expression in human periodontal ligament cells. Clin Exp Immunol. 2012;168:113-24.